SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parenteral Drugs trades jubilantly as its WOS executes agreement with Fresenius Kabi India

15 Mar 2013 Evaluate

Parenteral Drugs (India) is currently trading at Rs. 125.50, up by 6.80 points or 5.73% from its previous closing of Rs. 118.70 on the BSE.

The scrip opened at Rs. 129.00 and has touched a high and low of Rs. 130.55 and Rs. 123.30 respectively. So far 31194 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 130.55 on 15-March-2013 and a 52 week low of Rs. 51.05 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs. 130.55 and Rs. 107.00 respectively. The current market cap of the company is Rs. 331.10 crore.

The promoters holding in the company stood at 69.29% while Institutions and Non-Institutions held 1.78% and 28.94% respectively.

Parenteral Drugs India’s one of the wholly owned subsidiaries (WOS) - Goa Formulations has executed an agreement with Fresenius Kabi India to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs 200 crore, and the agreement has become binding on the parties. Further, Parenteral Drugs (India) has also accorded its consent to the transaction as the holding company.

Parenteral Drugs India is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose. The I.V. fluids are packed in size ranging from 100 ml to 3 litre and dialysis solution up to 10 litres water for injection is manufactured with the help of hi-tech From-Fill-seal machine ranging from 1 ml to 10 ml.

Parenteral Drugs Share Price

3.39 0.00 (0.00%)
21-Aug-2023 18:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.50
Dr. Reddys Lab 1233.20
Cipla 1232.00
Zydus Lifesciences 937.70
Lupin 2327.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×